LT2826776T - (r)-1(2,2-difluorbenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamido kieta amorfinės formos dispersija - Google Patents

(r)-1(2,2-difluorbenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamido kieta amorfinės formos dispersija

Info

Publication number: LT2826776T
Authority: LT; Lithuania
Prior art keywords: difluorobenzo; cyclopropanecarboxamide; methylpropan; dioxol; dihydroxypropyl
Prior art date: 2010-03-25

Application number

LTEP14172991.3T

Other languages

English (en)

Inventor

Ali Keshavarz-Shokri

Beili Zhang

Tim Edward Alcacio

Elaine Chungmin Lee

Yuegang Zhang

Mariusz Krawiec

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-25

Filing date

2011-03-25

Publication date

2021-01-11

2011-03-25 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2021-01-11 Publication of LT2826776T publication Critical patent/LT2826776T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)

LTEP14172991.3T 2010-03-25 2011-03-25 (r)-1(2,2-difluorbenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamido kieta amorfinės formos dispersija LT2826776T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US31737610P	2010-03-25	2010-03-25
US31995310P	2010-04-01	2010-04-01
US32156110P	2010-04-07	2010-04-07
US32163610P	2010-04-07	2010-04-07

Publications (1)

Publication Number	Publication Date
LT2826776T true LT2826776T (lt)	2021-01-11

Family

ID=43903962

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP14172991.3T LT2826776T (lt)	2010-03-25	2011-03-25	(r)-1(2,2-difluorbenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamido kieta amorfinės formos dispersija
LTPA2021508C LTPA2021508I1 (lt)	2010-03-25	2021-05-14

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2021508C LTPA2021508I1 (lt)	2010-03-25	2021-05-14

Country Status (24)

Country	Link
US (1)	US20110251253A1 (lt)
EP (5)	EP2826776B1 (lt)
JP (5)	JP5734410B2 (lt)
CN (3)	CN109081804B (lt)
AU (3)	AU2011230508B2 (lt)
BR (1)	BR112012024338B1 (lt)
CA (2)	CA3016080C (lt)
CY (2)	CY1123794T1 (lt)
DK (1)	DK2826776T3 (lt)
ES (4)	ES2951520T3 (lt)
FR (1)	FR21C1018I2 (lt)
HR (2)	HRP20230661T1 (lt)
HU (3)	HUE052759T2 (lt)
IL (4)	IL222117B (lt)
LT (2)	LT2826776T (lt)
MX (3)	MX345541B (lt)
NO (1)	NO2021021I1 (lt)
NZ (3)	NZ718018A (lt)
PL (2)	PL3835297T3 (lt)
PT (1)	PT2826776T (lt)
RS (1)	RS61314B1 (lt)
RU (2)	RU2711481C2 (lt)
SI (1)	SI2826776T1 (lt)
WO (1)	WO2011119984A1 (lt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CN101006076B (zh)	2004-06-24	2010-09-29	沃泰克斯药物股份有限公司	Atp-结合***转运蛋白的调控剂
WO2007021982A2 (en)	2005-08-11	2007-02-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
SI1945632T1 (sl) *	2005-11-08	2014-03-31	Vertex Pharmaceuticals Incorporated	Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
CN103214450B (zh)	2005-12-28	2016-10-05	弗特克斯药品有限公司	作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物
JP5409010B2 (ja)	2005-12-28	2014-02-05	バーテックスファーマシューティカルズインコーポレイテッド	Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
HUE036165T2 (hu)	2006-04-07	2018-06-28	Vertex Pharma	ATP-kötõ kazetta transzportereinek modulátorai
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
JP5497633B2 (ja)	2007-05-09	2014-05-21	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒのモジュレーター
CA2696298C (en)	2007-08-24	2016-09-06	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP2217572B1 (en)	2007-11-16	2013-11-06	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of atp-binding cassette transporters
WO2009076142A2 (en)	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
WO2009073757A1 (en)	2007-12-07	2009-06-11	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA3039943C (en)	2008-02-28	2021-07-13	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl)	2008-03-31	2015-11-30	Vertex Pharmaceuticals Incorporated	Piridilni derivati kot cftr-modulatorji
US8716338B2 (en)	2008-09-29	2014-05-06	Vertex Pharmaceuticals Incorporated	Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2821400B1 (en)	2009-03-20	2017-09-27	Vertex Pharmaceuticals Incorporated	Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2795804C (en)	2010-04-07	2021-10-26	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CA2795748C (en)	2010-04-07	2020-12-08	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR20130056244A (ko) *	2010-04-22	2013-05-29	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
US8563593B2 (en) *	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
KR101985044B1 (ko)	2011-11-08	2019-05-31	버텍스 파마슈티칼스 인코포레이티드	Atp-결합 카세트 수송체의 조절제
US20130172375A1 (en) *	2011-12-13	2013-07-04	Hoffmann-La Roche Inc.	Pharmaceutical composition
MX2014010253A (es)	2012-02-27	2014-11-12	Vertex Pharma	Composicion farmaceutica y administraciones de la misma.
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
US9783529B2 (en)	2013-03-13	2017-10-10	Flatley Discovery Lab, Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
CN104415345A (zh) *	2013-08-30	2015-03-18	天津药物研究院	一种多元复合物及其制备方法
CA2930199C (en)	2013-11-12	2022-10-25	Vertex Pharmaceuticals Incorporated	Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
PL3925607T3 (pl) *	2014-04-15	2023-10-30	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
NZ768373A (en)	2014-10-06	2024-03-22	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
WO2016057730A1 (en)	2014-10-07	2016-04-14	Strohmeier Mark	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107405337B (zh) *	2014-10-31	2021-02-09	艾伯维公司	取代的色满和使用方法
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
WO2016109362A1 (en)	2014-12-31	2016-07-07	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
WO2016160945A1 (en)	2015-03-31	2016-10-06	Concert Pharmaceuticals, Inc.	Deuterated vx-661
CN105130949B (zh) *	2015-09-02	2019-01-29	阜新奥瑞凯新材料有限公司	1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
HUP1600270A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600271A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US10570115B2 (en)	2016-09-30	2020-02-25	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10399940B2 (en)	2016-10-07	2019-09-03	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
AU2017371200B2 (en)	2016-12-09	2021-05-06	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3068609A1 (en)	2017-07-01	2019-01-10	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of cystic fibrosis
CA3069225A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
BR112020000941A2 (pt)	2017-07-17	2020-07-21	Vertex Pharmaceuticals Incorporated	métodos de tratamento para fibrose cística
ES2912657T3 (es)	2017-08-02	2022-05-26	Vertex Pharma	Procesos para preparar compuestos de pirrolidina
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
CN107880011B (zh) *	2017-11-27	2019-08-16	山东省医学科学院药物研究所	鲁玛卡托关键中间体的合成方法
US20210228489A1 (en)	2017-12-04	2021-07-29	Vertex Pharmaceuticals Incorporated	Compositions for treating cystic fibrosis
KR20200097293A (ko)	2017-12-08	2020-08-18	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
US11066417B2 (en)	2018-02-15	2021-07-20	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
CN110193012B (zh) *	2018-02-27	2022-02-08	江苏恒瑞医药股份有限公司	一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
WO2019195739A1 (en)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
ES2943126T3 (es)	2018-11-14	2023-06-09	Vertex Pharma	Métodos para el tratamiento de la fibrosis quística
CA3067611A1 (en)	2019-01-15	2020-07-15	Apotex Inc.	Processes for the preparation of tezacaftor and intermediates thereof
AR118555A1 (es)	2019-04-03	2021-10-20	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
US11884672B2 (en)	2019-05-14	2024-01-30	Vertex Pharmaceuticals Incorporated	Modulators of alpha-1 antitrypsin
WO2020242935A1 (en)	2019-05-29	2020-12-03	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
TW202120517A (zh)	2019-08-14	2021-06-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
US11873300B2 (en)	2019-08-14	2024-01-16	Vertex Pharmaceuticals Incorporated	Crystalline forms of CFTR modulators
EP4013759A1 (en)	2019-08-14	2022-06-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TW202115092A (zh)	2019-08-14	2021-04-16	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2021140525A1 (en) *	2020-01-07	2021-07-15	Msn Laboratories Private Limited, R&D Center	Novel crystalline form of 1-(2,2-difluoro-2h-1,3benzo dioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl}cyclopropane-1-carboxamide and its process for the preparation thereof
US20230092495A1 (en)	2020-03-06	2023-03-23	Química Sintética, S.A.	Solid forms of tezacaftor and processes for the preparation thereof
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022036060A1 (en)	2020-08-13	2022-02-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
CR20230197A (es)	2020-10-07	2023-07-06	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022076629A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20230200A (es)	2020-10-07	2023-07-13	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230416275A1 (en)	2020-10-07	2023-12-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373939A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076618A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076620A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076622A2 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
JP2023550345A (ja)	2020-11-17	2023-12-01	バーテックスファーマシューティカルズインコーポレイテッド	４－（５－（４－フルオロフェニル）－６－（テトラヒドロ－２ｈ－ピラン－４－イル）－１，５－ジヒドロピロロ［２，３－ｆ］インダゾール－７－イル）安息香酸の固体形態
KR20230118123A (ko)	2020-12-10	2023-08-10	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 치료 방법
WO2023150237A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2023150236A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023154291A1 (en)	2022-02-08	2023-08-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2023196429A1 (en)	2022-04-06	2023-10-12	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2023224924A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2024031081A1 (en)	2022-08-04	2024-02-08	Vertex Pharmaceuticals Incorporated	Compositions for the treatment of cftr-mediated diseases
WO2024056791A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2024056779A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
ES2287971T3 (es) *	1997-08-11	2007-12-16	Pfizer Products Inc.	Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
CA2402174A1 (en) *	2000-03-09	2001-09-13	Ono Pharmaceutical Co., Ltd.	Indole derivatives, process for preparation of the same and use thereof
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US20060083784A1 (en) *	2002-08-07	2006-04-20	Smithkline Beecham Corporation	Amorphous pharmaceutical compositions
CA2500498C (en)	2002-09-30	2012-08-21	The Regents Of The University Of California	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP2004131393A (ja) *	2002-10-08	2004-04-30	Kowa Co	易溶出性製剤
EP1601657A1 (en)	2003-03-12	2005-12-07	Vertex Pharmaceuticals Incorporated	Pyrazole modulators of atp-binding cassette transporters
ES2926542T3 (es)	2003-04-11	2022-10-26	Ptc Therapeutics Inc	Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
WO2004110352A2 (en)	2003-05-16	2004-12-23	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2004111014A1 (en)	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2005035514A2 (en)	2003-10-08	2005-04-21	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
AU2004290581B2 (en)	2003-11-14	2011-07-14	Vertex Pharmaceuticals Incorporated	Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
EA011074B1 (ru)	2004-03-30	2008-12-30	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Гидразидсодержащие соединения - ингибиторы cftr и их применение
AU2005251745A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP1799212A2 (en)	2004-10-13	2007-06-27	PTC Therapeutics, Inc.	Compounds for nonsense suppression, and methods for their use
EP2363128B1 (en)	2005-03-11	2016-02-17	Vertex Pharmaceuticals Incorporated	Indole modulators of ATP-binding cassette transporters
CA2600869A1 (en) *	2005-03-18	2006-09-28	The Regents Of The University Of California	Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2603402C (en)	2005-04-08	2017-10-31	Ptc Therapeutics, Inc.	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2006251624A1 (en)	2005-05-24	2006-11-30	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
CN101287732A (zh) *	2005-08-11	2008-10-15	沃泰克斯药物股份有限公司	囊性纤维化跨膜电导调节剂的调控剂
ES2414434T3 (es) *	2005-08-29	2013-07-19	Sanofi-Aventis U.S. Llc	Dispersiones sólidas amorfas de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida
CN101312722A (zh)	2005-10-06	2008-11-26	沃泰克斯药物股份有限公司	Atp-结合***转运蛋白的调控剂
MX2008011976A (es) *	2006-03-20	2009-04-07	Vertex Pharma	Composiciones farmaceuticas.
CN101494979A (zh) *	2006-03-20	2009-07-29	沃泰克斯药物股份有限公司	药物组合物
US7645789B2 (en) *	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
HUE036165T2 (hu) *	2006-04-07	2018-06-28	Vertex Pharma	ATP-kötõ kazetta transzportereinek modulátorai
US20080132560A1 (en) *	2006-11-21	2008-06-05	San-Laung Chow	Solid dispersion composition
KR101576695B1 (ko) *	2007-11-22	2015-12-10	젠야쿠코교가부시키가이샤	복소환식 화합물의 비정질체, 이를 포함하는 고체 분산체, 약제 및 그 제조법
WO2009073757A1 (en) *	2007-12-07	2009-06-11	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
AU2008363828B2 (en) *	2008-11-06	2016-09-08	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
EP2813227A1 (en) *	2009-10-22	2014-12-17	Vertex Pharmaceuticals Incorporated	Compositions for treatment of cystic fibrosis and other chronic diseases
KR20130056244A (ko) *	2010-04-22	2013-05-29	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
EP2560650A1 (en) *	2010-04-22	2013-02-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
CN103153287A (zh) *	2010-08-23	2013-06-12	弗特克斯药品有限公司	(R)-1-(2，2-二氟苯并[d][1，3]间二氧杂环戊烯-5-基)-N-(1-(2，3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用

2011
- 2011-03-25 AU AU2011230508A patent/AU2011230508B2/en active Active
- 2011-03-25 EP EP14172991.3A patent/EP2826776B1/en active Active
- 2011-03-25 ES ES20206423T patent/ES2951520T3/es active Active
- 2011-03-25 HU HUE14172991A patent/HUE052759T2/hu unknown
- 2011-03-25 EP EP17154840.7A patent/EP3181561B1/en active Active
- 2011-03-25 NZ NZ718018A patent/NZ718018A/en unknown
- 2011-03-25 BR BR112012024338-1A patent/BR112012024338B1/pt active IP Right Grant
- 2011-03-25 RS RS20210007A patent/RS61314B1/sr unknown
- 2011-03-25 CN CN201810927753.5A patent/CN109081804B/zh active Active
- 2011-03-25 ES ES17154840T patent/ES2804202T3/es active Active
- 2011-03-25 EP EP20206423.4A patent/EP3835297B1/en active Active
- 2011-03-25 HU HUE20206423A patent/HUE062892T2/hu unknown
- 2011-03-25 EP EP11713134.2A patent/EP2563778B1/en active Active
- 2011-03-25 HR HRP20230661TT patent/HRP20230661T1/hr unknown
- 2011-03-25 CN CN201180025743.9A patent/CN102892764B/zh active Active
- 2011-03-25 CA CA3016080A patent/CA3016080C/en active Active
- 2011-03-25 RU RU2015153068A patent/RU2711481C2/ru active
- 2011-03-25 RU RU2012145295/04A patent/RU2573830C2/ru active
- 2011-03-25 PL PL20206423.4T patent/PL3835297T3/pl unknown
- 2011-03-25 MX MX2016001939A patent/MX345541B/es unknown
- 2011-03-25 LT LTEP14172991.3T patent/LT2826776T/lt unknown
- 2011-03-25 ES ES11713134.2T patent/ES2604105T3/es active Active
- 2011-03-25 PT PT141729913T patent/PT2826776T/pt unknown
- 2011-03-25 JP JP2013501522A patent/JP5734410B2/ja active Active
- 2011-03-25 EP EP23166117.4A patent/EP4253381A3/en active Pending
- 2011-03-25 NZ NZ602665A patent/NZ602665A/en unknown
- 2011-03-25 PL PL14172991T patent/PL2826776T3/pl unknown
- 2011-03-25 DK DK14172991.3T patent/DK2826776T3/da active
- 2011-03-25 SI SI201131935T patent/SI2826776T1/sl unknown
- 2011-03-25 CN CN201610452877.3A patent/CN106083832A/zh active Pending
- 2011-03-25 CA CA2794559A patent/CA2794559C/en active Active
- 2011-03-25 NZ NZ700556A patent/NZ700556A/en unknown
- 2011-03-25 MX MX2012011062A patent/MX347804B/es active IP Right Grant
- 2011-03-25 MX MX2017001548A patent/MX370904B/es unknown
- 2011-03-25 US US13/072,380 patent/US20110251253A1/en not_active Abandoned
- 2011-03-25 WO PCT/US2011/030032 patent/WO2011119984A1/en active Application Filing
- 2011-03-25 ES ES14172991T patent/ES2845449T3/es active Active
2012
- 2012-09-24 IL IL222117A patent/IL222117B/en active IP Right Grant
2015
- 2015-03-09 JP JP2015046120A patent/JP2015127334A/ja active Pending
2016
- 2016-07-27 AU AU2016208341A patent/AU2016208341B2/en active Active
- 2016-10-20 JP JP2016206062A patent/JP6326570B2/ja active Active
2017
- 2017-12-21 JP JP2017245323A patent/JP6913623B2/ja active Active
2018
- 2018-02-15 IL IL257542A patent/IL257542B/en active IP Right Grant
- 2018-05-07 AU AU2018203149A patent/AU2018203149B2/en active Active
2019
- 2019-10-18 IL IL270047A patent/IL270047B/en unknown
2020
- 2020-03-18 JP JP2020047688A patent/JP6964702B2/ja active Active
2021
- 2021-02-01 HR HRP20210165TT patent/HRP20210165T1/hr unknown
- 2021-02-08 CY CY20211100108T patent/CY1123794T1/el unknown
- 2021-05-14 FR FR21C1018C patent/FR21C1018I2/fr active Active
- 2021-05-14 LT LTPA2021508C patent/LTPA2021508I1/lt unknown
- 2021-05-17 HU HUS2100019C patent/HUS2100019I1/hu unknown
- 2021-05-21 NO NO2021021C patent/NO2021021I1/no unknown
- 2021-11-25 IL IL288388A patent/IL288388A/en unknown
2023
- 2023-08-03 CY CY20231100390T patent/CY1126143T1/el unknown

Also Published As

Publication number	Publication date
LTPA2021508I1 (lt)	2021-06-10
RU2012145295A (ru)	2014-04-27
EP3835297C0 (en)	2023-06-07
ES2604105T3 (es)	2017-03-03
EP3181561B1 (en)	2020-05-20
AU2016208341A1 (en)	2016-08-18
CA2794559C (en)	2019-07-23
CN102892764B (zh)	2016-07-06
MX370904B (es)	2020-01-09
MX347804B (es)	2017-05-15
CN109081804A (zh)	2018-12-25
PL2826776T3 (pl)	2021-05-31
JP6964702B2 (ja)	2021-11-10
NZ700556A (en)	2016-04-29
NO2021021I1 (no)	2021-05-21
HRP20210165T1 (hr)	2021-03-19
RU2711481C2 (ru)	2020-01-17
IL257542A (en)	2018-04-30
FR21C1018I2 (fr)	2023-02-17
IL222117B (en)	2018-02-28
PT2826776T (pt)	2021-02-01
JP2020094068A (ja)	2020-06-18
JP6913623B2 (ja)	2021-08-04
CN102892764A (zh)	2013-01-23
JP5734410B2 (ja)	2015-06-17
ES2951520T3 (es)	2023-10-23
CN109081804B (zh)	2021-12-10
IL270047B (en)	2022-01-01
NZ718018A (en)	2017-10-27
JP6326570B2 (ja)	2018-05-23
CA2794559A1 (en)	2011-09-29
RS61314B1 (sr)	2021-02-26
AU2011230508B2 (en)	2016-04-28
HRP20230661T1 (hr)	2023-09-29
JP2017008120A (ja)	2017-01-12
CY1126143T1 (el)	2023-11-15
EP2563778A1 (en)	2013-03-06
ES2845449T3 (es)	2021-07-26
EP4253381A3 (en)	2023-11-01
CA3016080C (en)	2019-08-20
ES2804202T3 (es)	2021-02-04
JP2018048207A (ja)	2018-03-29
RU2573830C2 (ru)	2016-01-27
IL288388A (en)	2022-01-01
IL257542B (en)	2020-05-31
MX345541B (es)	2017-02-03
RU2015153068A3 (lt)	2019-07-17
BR112012024338B1 (pt)	2021-09-28
CA3016080A1 (en)	2011-09-29
HUS2100019I1 (hu)	2021-06-28
AU2011230508A1 (en)	2012-10-18
FR21C1018I1 (fr)	2021-07-02
AU2018203149B2 (en)	2019-07-25
WO2011119984A1 (en)	2011-09-29
EP3835297A1 (en)	2021-06-16
BR112012024338A2 (pt)	2020-09-01
PL3835297T3 (pl)	2023-09-11
EP2826776B1 (en)	2020-11-25
HUE052759T2 (hu)	2021-05-28
AU2018203149A1 (en)	2018-05-24
CY1123794T1 (el)	2021-09-14
EP3181561A1 (en)	2017-06-21
SI2826776T1 (sl)	2021-02-26
EP2826776A1 (en)	2015-01-21
NZ602665A (en)	2014-10-31
EP4253381A2 (en)	2023-10-04
MX2012011062A (es)	2013-01-14
US20110251253A1 (en)	2011-10-13
RU2015153068A (ru)	2019-01-17
DK2826776T3 (da)	2020-12-14
AU2016208341B2 (en)	2018-05-24
JP2015127334A (ja)	2015-07-09
CN106083832A (zh)	2016-11-09
HUE062892T2 (hu)	2023-12-28
EP2563778B1 (en)	2016-08-24
JP2013523655A (ja)	2013-06-17
EP3835297B1 (en)	2023-06-07

Publication	Publication Date	Title
HUS2100019I1 (hu)	2021-06-28	(R)-1(2,2-difluorbenzo(D)(1,3)dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi-2- metilpropán-2-il)-1H-indol-5-il)-ciklo-propánkarboxamid amorf formájának szilárd diszperziója
AP3179A (en)	2015-03-31	Benzofuranyl derivatives used as glucokinase inhibitors
GB0822104D0 (en)	2009-01-07	Criticality of data
HRP20160919T1 (hr)	2016-10-07	Benzodioksol ili benzodioksepin heterociklički spojevi kao inhibitori fosfodiesteraze
IT1395188B1 (it)	2012-09-05	Testa per apparecchiature video-fotografiche
NO20090798L (no)	2010-08-20	Beskyttelsesstruktur for beskyttelse av undersjoisk utstyr
IL214078A0 (en)	2011-08-31	Integrated desktop software for management of virus data
PL384427A1 (pl)	2009-08-17	Urządzenie do produkcji zrzezów
PL385894A1 (pl)	2010-03-01	Urządzenie do wibracyjnego odwadniania zawiesin
TH112451B (th)	2012-02-20	อุปกรณ์แกะถาดข้าวกล่อง
TH0901005765A (th)	2016-05-10	ข้อกำหนดขนาดใช้สำหรับตัวทำการของตัวรับ S1P (S1P Receptor Agonist)
PL386720A1 (pl)	2010-06-21	Sposób epoksydacji propylenu